Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
Emergent BioSolutions (NYSE:EBS) has announced that its Compensation Committee has approved an equity award for a new employee under its 2023 Inducement Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Emergent BioSolutions (NYSE:EBS) has announced that its Compensation Committee has approved an equity award for a new employee under its 2023 Inducement Plan. The award, granted on March 15, 2025, consists of restricted stock units and stock options totaling 72,882 shares of Emergent common stock. This equity grant was made in accordance with the NYSE Listing Rule 303A.08 employment inducement award exception. The awarded shares will fully vest on March 15, 2026, contingent upon the employee's continued service through the vesting date.
Details
News Market Reaction – EBS
The recorded move for EBS in the trading session of this news was -0.17%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the "Inducement Plan").
The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the “Equity Award”) as of March 15, 2025 in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The Equity Award will be fully vested on March 15, 2026, subject to the employee’s continuous service through the vesting date.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.